Patents by Inventor Paul David Robbins
Paul David Robbins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180339058Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: ApplicationFiled: July 30, 2018Publication date: November 29, 2018Applicant: Wyeth Holdings LLCInventors: Arthur KUNZ, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
-
Publication number: 20160303252Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: ApplicationFiled: May 3, 2016Publication date: October 20, 2016Applicant: Wyeth Holdings LLCInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
-
Patent number: 9351986Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: GrantFiled: March 7, 2014Date of Patent: May 31, 2016Assignee: WYETH HOLDINGS LLCInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
-
Patent number: 9249184Abstract: The present invention relates to Cardiac Targeting Peptides or CTPs that are able to transduce cardiomyocytes specifically in culture and in vivo, and to methods for using such peptides and their derivatives to deliver peptides, proteins or nucleic acids specifically to the heart. It is based, at least in part, on the discovery that the peptide APWHLSSQYSRT (SEQ ID NO:1) functioned as a cardiac-specific protein targeting peptide and was successful in delivering a number of different cargoes to cardiac muscle cells in vitro and in vivo.Type: GrantFiled: October 14, 2011Date of Patent: February 2, 2016Assignee: University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: Paul David Robbins, Maliha Zahid
-
Patent number: 8835611Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: GrantFiled: February 13, 2012Date of Patent: September 16, 2014Assignee: Wyeth Holdings LLCInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
-
Publication number: 20140235835Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: ApplicationFiled: March 7, 2014Publication date: August 21, 2014Applicant: WYETH HOLDINGS LLCInventors: ARTHUR KUNZ, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
-
Patent number: 8747857Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: GrantFiled: November 3, 2003Date of Patent: June 10, 2014Assignee: Wyeth Holdings LLCInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
-
Publication number: 20120244136Abstract: The present invention relates to Cardiac Targeting Peptides or CTPs that are able to transduce cardiomyocytes specifically in culture and in vivo, and to methods for using such peptides and their derivatives to deliver peptides, proteins or nucleic acids specifically to the heart. It is based, at least in part, on the discovery that the peptide APWHLSSQYSRT (SEQ ID NO:1) functioned as a cardiac-specific protein targeting peptide and was successful in delivering a number of different cargoes to cardiac muscle cells in vitro and in vivo.Type: ApplicationFiled: October 14, 2011Publication date: September 27, 2012Inventors: Paul David Robbins, Maliha Zahid
-
Publication number: 20120213804Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: ApplicationFiled: February 13, 2012Publication date: August 23, 2012Applicant: WYETH HOLDINGS CORPORATIONInventors: ARTHUR KUNZ, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
-
Patent number: 8153768Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: GrantFiled: May 2, 2003Date of Patent: April 10, 2012Assignee: Wyeth Holdings CorporationInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
-
Patent number: 6936468Abstract: The present invention relates to tolerogenic mammalian dendritic cells (DCs) and methods for the production of the tolerogenic DCs. In addition, the present invention provides a method for enhancing tolerogenicity in a host comprising administering the tolerogenic mammalian DCs of the present invention to the host. The tolerogenic DCs of the present invention comprise an oligodeoxyribonucleotide (ODN) which has one or more NF-?B binding sites. The tolerogenic DCs of the present invention may further comprise a viral vector, and preferably an adenoviral vector, which does not affect the tolerogenicity of the tolerogenic DCs when present therein. Enhanced tolerogenicity in a host is useful for prolonging foreign graft survival and for treating inflammatory related diseases, such as autoimmune diseases.Type: GrantFiled: April 27, 2001Date of Patent: August 30, 2005Assignee: University of PittsburghInventors: Paul David Robbins, Lina Lu, Nick Giannoukakis
-
Publication number: 20040192900Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: ApplicationFiled: November 3, 2003Publication date: September 30, 2004Applicant: Wyeth Holdings CorporationInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
-
Publication number: 20040082764Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: ApplicationFiled: May 2, 2003Publication date: April 29, 2004Applicant: Wyeth Holdings CorporationInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
-
Publication number: 20020048564Abstract: The present invention relates to tolerogenic mammalian dendritic cells (DCs) and methods for the production of the tolerogenic DCs. In addition, the present invention provides a method for enhancing tolerogenicity in a host comprising administering the tolerogenic mammalian DCs of the present invention to the host. The tolerogenic DCs of the present invention comprise an oligodeoxyribonucleotide (ODN) which has one or more NF-&kgr;B binding sites. The tolerogenic DCs of the present invention may further comprise a viral vector, and preferably an adenoviral vector, which does not affect the tolerogenicity of the tolerogenic DCs when present therein. Enhanced tolerogenicity in a host is useful for prolonging foreign graft survival and for treating inflammatory related diseases, such as autoimmune diseases.Type: ApplicationFiled: April 27, 2001Publication date: April 25, 2002Inventors: Paul David Robbins, Lina Lu, Nick Giannoukakis